Trial Profile
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2020
Price :
$35
*
At a glance
- Drugs Hydrocodone (Primary)
- Indications Back pain; Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Cephalon; Teva Branded Pharmaceutical Products R&D
- 30 Dec 2011 Actual patient number (391) and trial location (USA) added as reported by ClinicalTrials.gov.
- 30 Dec 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
- 30 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.